JP6296581B2 - 硝子体の視覚化のための組成物および方法 - Google Patents

硝子体の視覚化のための組成物および方法 Download PDF

Info

Publication number
JP6296581B2
JP6296581B2 JP2016574918A JP2016574918A JP6296581B2 JP 6296581 B2 JP6296581 B2 JP 6296581B2 JP 2016574918 A JP2016574918 A JP 2016574918A JP 2016574918 A JP2016574918 A JP 2016574918A JP 6296581 B2 JP6296581 B2 JP 6296581B2
Authority
JP
Japan
Prior art keywords
composition
vitreous
agent
seq
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016574918A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017524679A (ja
Inventor
ゴーシュ，ジョイ
ピーター ドライジャ，サデウス
ピーター ドライジャ，サデウス
ログスカ，マイケル
カールソン，エリック
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2017524679A publication Critical patent/JP2017524679A/ja
Application granted granted Critical
Publication of JP6296581B2 publication Critical patent/JP6296581B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
    • A61K49/0084—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion liposome, i.e. bilayered vesicular structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0089—Particulate, powder, adsorbate, bead, sphere
    • A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4718—Cytokine-induced proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
JP2016574918A 2014-06-25 2015-06-24 硝子体の視覚化のための組成物および方法 Active JP6296581B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462016731P 2014-06-25 2014-06-25
US62/016,731 2014-06-25
PCT/IB2015/054747 WO2015198245A1 (en) 2014-06-25 2015-06-24 Compositions and methods for visualization of the vitreous

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017239403A Division JP2018039847A (ja) 2014-06-25 2017-12-14 硝子体の視覚化のための組成物および方法

Publications (2)

Publication Number Publication Date
JP2017524679A JP2017524679A (ja) 2017-08-31
JP6296581B2 true JP6296581B2 (ja) 2018-03-20

Family

ID=53539753

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016574918A Active JP6296581B2 (ja) 2014-06-25 2015-06-24 硝子体の視覚化のための組成物および方法
JP2017239403A Withdrawn JP2018039847A (ja) 2014-06-25 2017-12-14 硝子体の視覚化のための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017239403A Withdrawn JP2018039847A (ja) 2014-06-25 2017-12-14 硝子体の視覚化のための組成物および方法

Country Status (8)

Country Link
US (1) US10537648B2 (https=)
EP (1) EP3160512B1 (https=)
JP (2) JP6296581B2 (https=)
CN (1) CN107206107A (https=)
AU (1) AU2015278744B2 (https=)
CA (1) CA2953682A1 (https=)
ES (1) ES2730398T3 (https=)
WO (1) WO2015198245A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025242919A1 (en) * 2024-05-24 2025-11-27 Navigo Proteins Gmbh Novel binding proteins for hyaluronic acid

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1733744A1 (en) 2005-06-17 2006-12-20 Ludwig-Maximilians-Universität München Method, dye and medicament for staining the internal limiting membrane and/or the capsule of an eye
JP4936508B2 (ja) * 2006-01-23 2012-05-23 独立行政法人国立国際医療研究センター 蛍光ナノ粒子を含む眼の硝子体染色剤及び染色方法
HUE026001T2 (en) * 2007-02-05 2016-04-28 Apellis Pharmaceuticals Inc Compstatin analogues for use in the treatment of the inflammatory condition of the respiratory system
US20110236310A1 (en) 2008-12-25 2011-09-29 Canon Kabushiki Kaisha Labeling composition for intraocular tissue, labeling method of intraocular tissue, and screening method
US8759298B2 (en) 2010-05-03 2014-06-24 Scott & White Healthcare Protein therapy for corneal inflammation, epithelial wound healing, and photoreceptor degeneration
WO2012135432A2 (en) 2011-03-29 2012-10-04 Kemin Industries, Inc. Dyes for membranes and biological structures
JP6162707B2 (ja) * 2011-10-24 2017-07-12 ハロザイム インコーポレイテッド 抗ヒアルロナン剤治療のためのコンパニオン診断およびその使用方法
EP3838293A1 (en) * 2012-07-11 2021-06-23 Tissuetech, Inc. Compositions containing hc-ha/ptx3 complexes and methods of use thereof
TW201427989A (zh) 2012-12-18 2014-07-16 Novartis Ag 長效性蛋白質之組合物及方法
GB201400994D0 (en) * 2014-01-21 2014-03-05 Ucl Business Plc Drug delivery system

Also Published As

Publication number Publication date
US20170202981A1 (en) 2017-07-20
CA2953682A1 (en) 2015-12-30
US10537648B2 (en) 2020-01-21
WO2015198245A1 (en) 2015-12-30
JP2017524679A (ja) 2017-08-31
EP3160512A1 (en) 2017-05-03
ES2730398T3 (es) 2019-11-11
CN107206107A (zh) 2017-09-26
AU2015278744A1 (en) 2017-01-12
JP2018039847A (ja) 2018-03-15
EP3160512B1 (en) 2019-05-22
AU2015278744B2 (en) 2018-09-27

Similar Documents

Publication Publication Date Title
CN115461040B (zh) 含有酪氨酸激酶抑制剂的眼用植入物
CN115066232B (zh) 用于治疗眼病的组合物和方法
Fernández-Colino et al. Self-assembling elastin-like hydrogels for timolol delivery: development of an ophthalmic formulation against glaucoma
TW201836646A (zh) 治療與血管生成及血管新生相關病症的方法
RU2561585C2 (ru) Местный глазной пептидный состав
JP2009501727A (ja) 巨大分子集合体の存在に関連した状態、特に眼科障害の治療
ES2727293T3 (es) Métodos de inhibición de cataratas y presbicia
Giri et al. Gellan gum and sodium alginate in-situ gel of monocaprin for effective corneal permeation
AU2020230409B2 (en) Method for the treatment of a disease using pigment epithelium-derived factor (PEDF)
CA2726502A1 (en) In situ gelling systems as sustained delivery for front of eye
ES2869943T3 (es) Sistema de administración transmembrana de medicamentos
JP6296581B2 (ja) 硝子体の視覚化のための組成物および方法
US20230054032A1 (en) Compositions and methods for treating ocular disease
CN109640973A (zh) 近视的治疗
US11160881B2 (en) Dendrimer compositions for use in angiography
WO2023220676A9 (en) Chemerin-containing formulation for treating dry eye disease
CN119192407B (zh) 一种多肽-地塞米松偶联物及其制备方法与应用
KR20220051791A (ko) Fas 신호전달 억제용 펩타이드를 포함하는 황반변성 예방 또는 치료용 조성물
Kenwat et al. Reverse engineering strategy in complex ophthalmic product
Liu et al. Bioactive nanofiber hydrogel acts on VEGF and VEGF receptor to unleash inhibition effects on corneal neovascularization
JP2021522215A (ja) 蛍光マーカーの鼻腔内送達
CN115869416A (zh) 用于眼部靶向递药的细胞膜、药物载体、组合物及其制备方法和用途
Chaw Fundamental study of nanoliposomes for ocular therapy
Addo Development of novel encapsulated formulations using albumin-chitosan as a polymer matrix for ocular drug delivery
Asensio et al. The effect of a combination of 0.1% tetracaine HCl and 0.4% oxybuprocaine HCl on human central corneal thickness measurements

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170303

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170303

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170926

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20171010

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20171012

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171214

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180214

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180215

R150 Certificate of patent or registration of utility model

Ref document number: 6296581

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250